NCT04931667: A trial that was reported late by Biosplice Therapeutics, Inc.
This trial has reported, although it was 1094 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT04931667 |
|---|---|
| Title | A 3-Year, Multicenter, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Intra-articular Lorecivivint in Subjects With Osteoarthritis of the Knee in a Real-World Setting (STRIDES-EXTRA) |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | July 15, 2021 |
| Completion date | Dec. 13, 2021 |
| Required reporting date | Dec. 13, 2022, midnight |
| Actual reporting date | Dec. 11, 2025 |
| Date last checked at ClinicalTrials.gov | March 26, 2026 |
| Days late | 1094 |